Yoga guru Ramdev”s Patanjali has claimed to discover Ayurved-based medicine which can treat COVID-19 patients in as many as seven days. The firm announced that medicines ”Coronil and Swasari” have shown 100 per cent favourable results during clinical trials on COVID-19 infected patients except those on a life support system.
In a press conference Ramdev said, “The whole country and the world was waiting for medicine or vaccine for coronavirus. We are proud to announce that the first Ayurvedic, clinically controlled trial based evidence and research-based medicine has been prepared by the combined efforts of Patanjali Research Centre and NIMS.”
“We conducted a clinical case study and clinical controlled trial, and found 69 per cent patients recovered in 3 days and 100 patients recovered in 7 days,” he added. Meanwhile, the Ministry of AYUSH has asked the yoga guru Ramdev’s Patanjali Ayurved Ltd to stop advertising and publicising claims that it has found cure for COVID-19 till the issue is duly examined.
The Ministry has also sought details of the medicines. “Patanjali Ayurved Ltd has been asked to provide at the earliest details of the name and composition of the medicines being claimed for COVID treatment; site(s)/hospital(s), where the research study was conducted for COVID-19; protocol, sample size, Institutional Ethics Committee clearance, CTRI registration and results data of the study (ies) and stop advertising/publicizing such claims till the issue is duly examined,” the Ministry of AYUSH said in a press statement. “Ministry has also requested concerned State Licensing Authority of Uttarakhand Government to provide copies of license and product approval details of the Ayurvedic medicines being claimed for the treatment of COVID -19,” the statement added.
At a time when Corona has wreaked havoc, claiming millions of lives worldwide, spotlight is on its remedy—drug and vaccine. Recently Glenmark Pharmaceuticals received approval from the government’s drug regulator to market and manufacture oral antiviral drug Favipiravir for treating mild to moderate COVID-19 patients in the country.
Meanwhile, total positive cases continue to mount. The total tally has crossed 4.5 lakh with Maharashtra, Delhi, and Tamil Nadu top affecting states.